In a feeding trial, inflammation markers moved with weight, not diet quality

A small trial published in Cell Metabolism on October 21 asked a narrow question. If you improve what people eat but keep their weight steady, do markers of inflammation in the blood go down? In this study, they didn't. They moved only after the volunteers started losing weight.

How the trial was set up

The team, led by Warmbrunn, Tosti, Biswas and Bertozzi, ran a 16-week controlled-feeding trial with 53 adults who had metabolic risk factors. The group was 77% women, with a mean age of 54.7. Controlled feeding means the researchers supplied the food, so they knew what each person ate.

The trial had two phases. For the first 8 weeks, one group ate a Mediterranean diet and the other kept eating a usual Western diet. For the second 8 weeks, twice-weekly fasting days were added on top.

The main outcome was high-sensitivity C-reactive protein, a blood marker often used as a general readout of inflammation.

What changed, and when

In the first phase, better diet quality did improve blood lipids. It did not move the inflammation markers. The primary outcome stayed flat while weight stayed roughly the same.

Once the fasting days began, the picture changed. In the Mediterranean group, the marker fell relative to the control group. That drop came with greater weight loss, better insulin sensitivity and lower blood pressure.

The authors attribute the effect to weight loss and negative energy balance, not to the quality of the diet alone. Wider molecular analyses pointed the same way, showing reduced inflammatory signaling. Gut microbiome composition stayed largely stable across the trial.

Why the timing matters

Diet studies often change several things at once. People eat differently, eat less and lose weight, and it becomes hard to say which change did the work. Here the two phases split those effects apart in time. That is the useful part of the design.

It is also a small trial. 53 people, mostly women, over 16 weeks, is enough to see a signal but not enough to settle the question for everyone. The journal ran a companion commentary the same day on how to read diet-specific effects that follow weight loss, which is a fair sign the debate isn't closed.

The study also doesn't tell anyone what to eat. It describes what happened to a set of blood markers under tightly controlled conditions.

Where Soma fits

The broader lesson is one we keep coming back to. A single number can change for reasons that sit underneath it, and timing is often what tells them apart. Seeing that takes repeated readings taken the same way.

Soma is a general wellness product, not a medical device. It doesn't diagnose anything, and it doesn't measure blood markers. Soma Axon, the pod we are still building, takes the same light, cameras and stance every week, and shows each value with its margin of error, so a change over time is easier to trust. We wrote more about that in The same instrument, every week.

Sources, as of October 24, 2026: Warmbrunn, Tosti, Biswas, Bertozzi et al., Cell Metabolism and the journal's article page. This post describes research and isn't medical advice.